Previous 10 | Next 10 |
Xeris Pharmaceuticals (NASDAQ: XERS ) has priced its public offerings of 7.4M shares of common stock at $2.72/share for gross proceeds of ~$20.1M, and $75M of 5.00% Convertible Senior Notes due 2025. More news on: Xeris Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced the pricing of concurrent underwritten public offerings of 7,400,000 s...
Gainers: Ekso Bionics EKSO +138% . More news on: Puhui Wealth Investment Management Co., Ltd., Vaxart, Inc., PaySign, Inc., Stocks on the move, , Read more ...
Gainers: ALLY +14.7% . BBD +7.9% . CLPS +7.1% . NVST +5.1% . HLX +4.1% . More news on: Ally Financial Inc., Banco Bradesco S.A., CLPS Incorporation, Stocks on the move, , Read more ...
Xeris Pharmaceuticals (NASDAQ: XERS ) commences concurrent public offerings of $20M of common stock and $60M of convertible senior notes due 2025. More news on: Xeris Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has commenced concurrent underwritten public offerings of $20,...
Xeris Pharma Reports Positive Topline Data for Insulin Trial Xeris Pharmaceuticals ( XERS ) reported positive data for its Phase 2 clinical trial for diabetes. The drug candidate XP-3924 is an o-formulation of pramlintide and insulin and the trial aimed to assess its potential in treati...
Xeris Pharmaceuticals (NASDAQ: XERS ) announces positive results from a Phase 2 clinical trial evaluating candidate XP-3924, a co-formulation of pramlintide and insulin, in adults with type 1 diabetes (T1D). More news on: Xeris Pharmaceuticals, Inc., Healthcare stocks news, Stocks on t...
XP-3924 resulted in a 62% reduction of hyperglycemia after a glucose challenge XP-3924 showed improved glucose control when compared to Humulin® R alone XP-3924 showed promising glucose control when compared to both Humulin® R and co-administered injections of Humulin...
Results show a pre-treatment with a micro dose (150 µg) of Gvoke RTU Micro significantly prevented Exercise-Induced Hypoglycemia (EIH) during prolonged, moderate-to-high intensity aerobic exercise in a real-world setting with or without adjustment to insulin Study achieved all pri...
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the C...
John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track reco...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2024, the Compensation Committee of Xeris’ Boar...